Reflection paper on the EU Pharmaceutical Strategy

  29 January 2021

The BEAM Alliance welcomes the European Commission’s Pharmaceutical Strategy, which recognises the development of novel antimicrobials as a prime example of an unmet medical need and proposes important measures to address the rising threat of antimicrobial resistance (AMR),
which requires urgent action. We count on the Commission to foster short-term solutions in parallel to long-term incentive reforms, and to consider the specific challenges faced by European small and medium-sized enterprises (SMEs) in the field. Europe’s preparedness for the next global health crisis may be tested sooner than its legislative pace can keep up with.

Further reading: BEAM Alliance
Author(s): Beam Alliance
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





EADA 2023

Emerging Antimicrobials and Diagnostics in AMR 2023

International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands
16/17 November

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!